Responses
Regular and young investigator award abstracts
Checkpoint blockade therapy
201 Carboplatin, paclitaxel and pembrolizumab for the first line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
